Syndax Pharmaceuticals (SNDX) director receives 24,000 RSUs

Rhea-AI Filing Summary

Syndax Pharmaceuticals director Martin H. Huber Jr. received an award of 24,000 shares in the form of restricted stock units on February 4, 2026, at a price of $0 per share. After this grant, he beneficially owns 103,000 shares of common stock in direct form.

The restricted stock units vest one year from the grant date. The underlying shares will not be delivered and cannot be transferred or sold until the earlier of a separation from service, death, disability, or a change in control of the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Huber Martin H. Jr.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	24,000	$0.00	--

Holdings After Transaction: Common Stock — 103,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Huber Martin H. Jr.

(Last) (First) (Middle)

C/O SYNDAX PHARMACEUTICALS, INC.

730 THIRD AVENUE, FLOOR 9

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Syndax Pharmaceuticals Inc [ SNDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/04/2026		A		24,000(1)	A	$0	103,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.

	/s/ Michael A. Metzger, as Attorney-in-Fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Syndax Pharmaceuticals (SNDX) disclose in this Form 4 filing?

Syndax Pharmaceuticals reported that director Martin H. Huber Jr. received 24,000 restricted stock units at $0 per share. Following this equity grant, he beneficially owns 103,000 shares of common stock in direct ownership, according to the filing’s ownership table.

How many Syndax (SNDX) shares were granted to the director in this transaction?

The director was granted 24,000 shares in the form of restricted stock units. These units represent rights to receive common stock in the future, subject to vesting conditions and delivery restrictions described in the accompanying explanatory footnote.

What is the vesting schedule for the 24,000 restricted stock units at Syndax (SNDX)?

The 24,000 restricted stock units vest one year from the grant date. This means the director earns full rights to the underlying shares after one year, assuming continued service and subject to the specified triggering and delivery conditions.

When can the granted Syndax (SNDX) restricted stock units be delivered or sold?

The shares underlying the restricted stock units will not be delivered and cannot be transferred or sold until the earlier of separation from service, death, disability, or a change in control. These conditions delay actual share receipt and any potential sale.

How many Syndax (SNDX) shares does the director own after this equity award?

After the reported transaction, the director beneficially owns 103,000 shares of Syndax common stock. The filing classifies this as direct ownership, reflecting his total holdings following the 24,000-share restricted stock unit grant.

Was cash paid for the Syndax (SNDX) restricted stock unit grant?

No cash was paid for this grant; the transaction price per share is reported as $0. The award represents equity-based compensation rather than a market purchase of Syndax common stock by the director.